Skip to main content
Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.